Article Details

Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire

Retrieved on: 2024-11-16 15:31:31

Tags for this article:

Click the tags to see associated articles and topics

Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire. View article details on hiswai:

Summary

The article discusses Intellia Therapeutics' CRISPR-based treatment for ATTR amyloidosis, focusing on protein folding and its role in disease progression. It reports on a study showing improved outcomes and safety in patients, related to tags like Transthyretin and Vutrisiran.

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up